Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: A large-scale, multicentre study

The Lancet Oncology

Volumn 13, Issue 8, 2012, Pages 817-826

  Shen, Qiujin ^a   Fan, Jia ^b   Yang, Xin Rong ^b   Tan, Yexiong ^c   Zhao, Weifeng ^d   Xu, Yang ^b   Wang, Ning ^a   Niu, Yongdong ^a   Wu, Zheng ^a   Zhou, Jian ^b   Qiu, Shuang Jian ^b   Shi, Ying Hong ^b   Yu, Bin ^a   Tang, Ning ^a   Chu, Wei ^a   Wang, Min ^c   Wu, Jinhua ^d   Zhang, Zhigang ^a   Yang, Shengli ^a   Gu, Jianren ^a   Wang, Hongyang ^a,c   Qin, Wenxin ^a   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DICKKOPF 1 PROTEIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84864359563     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70233-4     Document Type: Article

References (36)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(suppl 4):5-13.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
4. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009, 3:353-367.
5. Qin LX, Tang ZY Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004, 130:497-513.
6. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009, 361:1437-1447.
7. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
8. Taketa K Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990, 12:1420-1432.
9. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol 2006, 101:524-532.
10. El-Serag HB, Marrero JA, Rudolph L, Reddy KR Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763.
11. Johnson PJ The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001, 5:145-159.
12. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391:357-362.
13. Krupnik VE, Sharp JD, Jiang C, et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999, 238:301-313.
14. Fedi P, Bafico A, Nieto Soria A, et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 1999, 274:19465-19472.
15. MacDonald BT, Tamai K, He X Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26.
16. Qin WX, Zhang HT, Yu YJ, et al. Uses of DKK-1 protein in diagnosis of cancer. Patent, WO/2007/104181 A1; published Sept 20, 2007.
17. Yu B, Yu YJ, You HY, et al. Expression and mutation analysis of DKK1 gene in human hepatocellular carcinoma. Zhongliu 2006, 26:662-665. [in Chinese].
18. Yu YJ, Wan XZ, Yu B, et al. Expression of Dickkopf (DKK1) in liver cancer and in multiple human cancer cell lines. Zhongliu 2006, 26:1109-1112. [in Chinese].
19. Yu B, Yang X, Xu Y, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear β-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol 2009, 50:948-957.
20. Sato N, Yamabuki T, Takano A, et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 2010, 70:5326-5336.
21. Tung EK, Mak CK, Fatima S, et al. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int 2011, 31:1494-1504.
22. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.
23. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
24. Lok AS, McMahon BJ Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
25. Sheng SL, Huang G, Yu B, Qin WX Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem 2009, 55:1656-1664.
26. Liaw Y-F, Chu C-M Hepatitis B virus infection. Lancet 2009, 373:582-592.
27. Wagner PD, Verma M, Srivastava S Challenges for biomarkers in cancer detection. Ann N Y Acad Sci 2004, 1022:9-16.
28. Tsai HC, Baylin SB Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011, 21:502-517.
29. Hundt S, Haug U, Brenner H Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007, 16:1935-1953.
30. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010, 55:2744-2755.
31. Brawley OW, Ankerst DP, Thompson IM Screening for prostate cancer. CA Cancer J Clin 2009, 59:264-273.
32. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24:5313-5327.
33. Kulasingam V, Diamandis EP Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008, 5:588-599.
34. Yamabuki T, Takano A, Hayama S, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007, 67:2517-2525.
35. Poon D, Anderson BO, Chen L-T, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1111-1118.
36. Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008, 68:1396-1404.